Medtronic has completed its acquisition of CathWorks, enhancing its cardiovascular diagnostics portfolio with advanced AI-powered coronary assessment technology.

Glimpse:

Announced on April 20, 2026, Medtronic finalized the acquisition of CathWorks in a deal valued at $585 million, with additional earn out payments possible. The move integrates CathWorks’ FFRangio® system an AI-driven, non-invasive diagnostic tool for coronary artery disease into Medtronic’s cardiovascular portfolio.

Medtronic has completed its acquisition of CathWorks, a medical device company specializing in advanced diagnostics for coronary artery disease (CAD), marking a significant step in strengthening its cardiovascular technology portfolio.

The transaction, valued at $585 million with potential additional earn out payments, follows Medtronic’s earlier strategic partnership with CathWorks established in 2022.

At the core of the acquisition is the FFRangio® System, a cutting edge diagnostic platform that uses artificial intelligence and computational modeling to assess coronary artery disease directly from standard angiograms. Unlike traditional methods, the system is drug free and wire free, reducing procedure complexity while providing a comprehensive physiological assessment of the coronary arteries.

The technology has already been commercialized across major markets including the United States, Europe, and Japan, and is supported by clinical evidence from the ALL-RISE trial, which involved over 1,900 patients globally. The study demonstrated that the system delivers results comparable to traditional invasive methods while improving efficiency and reducing procedure time.

By integrating CathWorks’ technology, Medtronic aims to expand its interventional cardiology offerings and improve diagnostic accuracy in cardiac care. The acquisition aligns with the company’s broader strategy to invest in AI-driven and minimally invasive solutions that enhance patient outcomes and streamline clinical workflows.

Industry analysts note that the move reflects a growing shift toward non invasive, AI-powered diagnostics in cardiovascular medicine, where faster, safer, and more scalable solutions are becoming increasingly important.

Overall, the acquisition positions Medtronic to further strengthen its leadership in cardiovascular care by combining advanced diagnostics with its existing therapeutic technologies.